Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Idiopathic thrombocytopenic purpura following allogeneic bone marrow transplantation – treatment with anti-D immunoglobulin

Abstract

A 38-year-old man developed idiopathic thrombocytopenic purpura (ITP) 8 months following allogeneic BMT while being treated for cGVHD with corticosteroids and tacrolimus (FK506). He received two courses of high-dose intravenous immunoglobulin (IvIG) which resulted in transient improvement. A single dose of intravenous anti-D immunoglobulin induced a durable response. Anti-D immunoglobulin is better tolerated, less complicated to administer, and less expensive than a course of IvIG.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, S., Churchill, W., Konugres, A. et al. Idiopathic thrombocytopenic purpura following allogeneic bone marrow transplantation – treatment with anti-D immunoglobulin. Bone Marrow Transplant 19, 173–174 (1997). https://doi.org/10.1038/sj.bmt.1700634

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1700634

Keywords

This article is cited by

Search

Quick links